WeightWatchers Gets a Makeover With Obesity-Drug Business

[ad_1] Markets Heard on the Street The decision to get into the business for drugs such as Ozempic makes sense [ad_2] Source link

British doctor pioneers low-carb diet as cure for obesity and type 2 diabetes

[ad_1] A red-brick surgery in the seaside resort of Southport in the north-west of England is on the frontline of one of the biggest questions facing the NHS: what’s the…

Hype Around Weight-Loss Drugs Shows No Signs of Abating. Neither Do the Ads.

[ad_1] Ads for the likes of Ozempic and Wegovy are spreading through social media feeds, subway stations and TV. [ad_2] Source link

Novo Nordisk Is Raising the Bar on Diabetes, Obesity Drugs — Analysis

[ad_1] Novo Nordisk is currently relaunching its diabetes drug Wegovy in the U.S., with rising capacity putting the company in a solid position to boost growth, according to analysts. [ad_2]…

Americans to Be Barred From Buying Ozempic in British Columbia

[ad_1] Provincial health officials urged doctors and pharmacists to make sure people are taking the drug to treat diabetes, not lose weight. [ad_2] Source link

Global Diabetes Diagnostics Business Report 2023-2030: Quality Products at Low Prices – The Mantra for Success in the Marketplace

[ad_1] DUBLIN, March 22, 2023 /PRNewswire/ — The “Diabetes Diagnostics: Global Strategic Business Report” report has been added to  ResearchAndMarkets.com’s offering. Research and Markets Logo Global Diabetes Diagnostics Market to Reach…

Eli Lilly Is Priced for Perfection in the Obesity Market

[ad_1] The company has outperformed its pharma peers in recent years, but its valuation leaves little room for error. [ad_2] Source link

Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78%

[ad_1] Health Sanofi says it would cap patients’ out-of-pocket costs for Lantus insulin at $35 a month [ad_2] Source link

In victory for people with diabetes, Sanofi announces insulin price caps, the last of 3 major insulin makers to do so

[ad_1] Sanofi will cap the out-of-pocket cost of its most popular insulin, Lantus, at $35 per month for people with private insurance, the French drugmaker said Thursday. The change will…

WSJ News Exclusive | Novo Nordisk to Slash Insulin Prices by Up to 75%

[ad_1] WSJ News Exclusive Health The insulin maker is the latest to plan sharp price cuts for the diabetes treatments to make them more affordable [ad_2] Source link